• Precision Peptide ordered 20,000 Thymosin Alpha-1 transdermal patches for its initial commercial production run.
• Each patch is formulated to deliver 2 mg of TA1 in a needle-free format.
• Manufacturing and testing will be completed in the U.S. under the company’s product infrastructure.
• Finished units are expected in January 2027, with commercial release to follow pending final quality review.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. The Precision Peptide Company Inc. published the original content used to generate this news brief via Newsfile (Ref. ID: 202610071338NEWSFILECNPR____20261007_317946_1) on October 07, 2026, and is solely responsible for the information contained therein.